Your browser doesn't support javascript.
loading
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study.
Rombach, Ines; Iftikhar, Marvi; Jhuti, Gurleen S; Gustavsson, Anders; Lecomte, Pascal; Belger, Mark; Handels, Ron; Castro Sanchez, Amparo Y; Kors, Jan; Hopper, Louise; Olde Rikkert, Marcel; Selbæk, Geir; Stephan, Astrid; Sikkes, Sietske A M; Woods, Bob; Gonçalves-Pereira, Manuel; Zanetti, Orazio; Ramakers, Inez H G B; Verhey, Frans R J; Gallacher, John; Landeiro, Filipa; Gray, Alastair M.
Afiliação
  • Rombach I; Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Old Road Campus, Oxford, OX3 7LF, United Kingdom. ines.rombach@ndorms.ox.ac.uk.
  • Iftikhar M; Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Old Road Campus, Oxford, OX3 7LF, United Kingdom.
  • Jhuti GS; Global Access, Centre of Excellence F.Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.
  • Gustavsson A; Quantify Research, Stockholm, 112 21, Sweden.
  • Lecomte P; Division of Neurogeriatrics, Department for Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, 171 64, Sweden.
  • Belger M; Global Head Health Economic Modelling and Methodology, Novartis Pharma AG, 4002, Basel, Switzerland.
  • Handels R; Global Statistical Sciences, Eli Lilly and company, Erl Wood Manor, Windlesham, GU20 6PH, United Kingdom.
  • Castro Sanchez AY; Division of Neurogeriatrics, Department for Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, 171 64, Sweden.
  • Kors J; Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, 6200 MD, The Netherlands.
  • Hopper L; Global Access, Centre of Excellence F.Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.
  • Olde Rikkert M; Department of Medical Informatics, Erasmus MC-University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
  • Selbæk G; School of Psychology, Dublin City University, Dublin 9, Ireland.
  • Stephan A; Department of Geriatrics, Radboudumc Alzheimer Center, Donders Center for Medical Neuroscience, Radboud University Medical Center, Nijmegen, 6525 GA, The Netherlands.
  • Sikkes SAM; National Advisory Unit of Ageing and Health, Vestfold Hospital Trust, 3103, Tønsberg, Norway.
  • Woods B; Department of Geriatric Medicine, Oslo University Hospital, Oslo, 0372, Norway.
  • Gonçalves-Pereira M; Faculty of Medicine, University of Oslo, Oslo, 0372, Norway.
  • Zanetti O; Institute for Health and Nursing Science, Martin Luther University Halle-Wittenberg, Halle (Saale), 06112, Germany.
  • Ramakers IHGB; Alzheimer Center Amsterdam, Amsterdam University Medical Centers/Amsterdam Neuroscience, Amsterdam, 1007 MB, The Netherlands.
  • Verhey FRJ; Dementia Services Development Centre Wales (DSDC), Bangor University, Bangor, LL57 2PZ, United Kingdom.
  • Gallacher J; Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, 1169-056, Portugal.
  • Actifcare Consortium; CHRC (Comprehensive Health Research Centre), Lisbon, Portugal.
  • LeARN Consortium; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, 25125, Italy.
  • Landeiro F; Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, 6200 MD, The Netherlands.
  • Gray AM; Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University Medical Center, Maastricht, 6200 MD, The Netherlands.
Qual Life Res ; 30(3): 867-879, 2021 Mar.
Article em En | MEDLINE | ID: mdl-33068236
ABSTRACT

PURPOSE:

The Quality of Life Alzheimer's Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorithm to obtain EQ-5D indices when only QoL-AD data are available.

METHODS:

Different statistical models to estimate utility directly, or responses to individual EQ-5D questions (response mapping) from QoL-AD, were trialled for patient-rated and proxy-rated questionnaires. Model performance was assessed by root mean square error and mean absolute error.

RESULTS:

The response model using multinomial regression including age and sex, performed best in both the estimation dataset and an independent dataset.

CONCLUSIONS:

The recommended mapping algorithm allows researchers for the first time to estimate EQ-5D values from QoL-AD data, enabling cost-utility analyses using datasets where the QoL-AD but no utility measures were collected.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Doença de Alzheimer Tipo de estudo: Qualitative_research / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Doença de Alzheimer Tipo de estudo: Qualitative_research / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article